JP2015501155A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501155A5
JP2015501155A5 JP2014539019A JP2014539019A JP2015501155A5 JP 2015501155 A5 JP2015501155 A5 JP 2015501155A5 JP 2014539019 A JP2014539019 A JP 2014539019A JP 2014539019 A JP2014539019 A JP 2014539019A JP 2015501155 A5 JP2015501155 A5 JP 2015501155A5
Authority
JP
Japan
Prior art keywords
wing segment
modified oligonucleotide
modified
linked nucleosides
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014539019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061984 external-priority patent/WO2013063313A1/en
Publication of JP2015501155A publication Critical patent/JP2015501155A/ja
Publication of JP2015501155A5 publication Critical patent/JP2015501155A5/ja
Pending legal-status Critical Current

Links

JP2014539019A 2011-10-25 2012-10-25 Ｇｃｃｒ発現のアンチセンス調整 Pending JP2015501155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551378P 2011-10-25 2011-10-25
US61/551,378 2011-10-25
PCT/US2012/061984 WO2013063313A1 (en) 2011-10-25 2012-10-25 Antisense modulation of gccr expression

Publications (2)

Publication Number Publication Date
JP2015501155A JP2015501155A (ja) 2015-01-15
JP2015501155A5 true JP2015501155A5 (enExample) 2015-12-10

Family

ID=48168513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539019A Pending JP2015501155A (ja) 2011-10-25 2012-10-25 Ｇｃｃｒ発現のアンチセンス調整

Country Status (14)

Country Link
US (2) US8901098B2 (enExample)
EP (1) EP2771463A4 (enExample)
JP (1) JP2015501155A (enExample)
KR (1) KR20140084232A (enExample)
CN (1) CN103906838A (enExample)
AU (2) AU2012328680A1 (enExample)
BR (1) BR112014009790A2 (enExample)
CA (1) CA2853373A1 (enExample)
HK (1) HK1201555A1 (enExample)
IL (1) IL232183A0 (enExample)
IN (1) IN2014CN03749A (enExample)
MX (1) MX350944B (enExample)
RU (1) RU2014119787A (enExample)
WO (1) WO2013063313A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20152002A1 (es) 2013-05-01 2016-01-21 Isis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de ttr y vhb
ES2812099T3 (es) 2014-05-01 2021-03-16 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3722424A1 (en) * 2015-04-16 2020-10-14 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
WO2017059205A1 (en) * 2015-09-30 2017-04-06 Ionis Pharmaceuticals, Inc. Combination therapy
US10083668B2 (en) 2016-03-09 2018-09-25 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device, display device, and electronic device
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
MY201698A (en) 2017-10-20 2024-03-13 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
JP2021511042A (ja) 2018-01-16 2021-05-06 ディセルナ ファーマシューティカルズ インコーポレイテッド Ａｌｄｈ２発現を阻害するための組成物及び方法
AU2020221892A1 (en) 2019-02-12 2021-08-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for inhibiting expression of CYP27A1
CN109680095A (zh) * 2019-02-25 2019-04-26 广西中医药大学 一种鉴定苦玄参品种的ssr引物组合物及其品种鉴定方法
CA3135402A1 (en) 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
IL296549A (en) 2020-03-18 2022-11-01 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting angptl3 expression
CA3187220A1 (en) 2020-08-04 2022-02-10 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
JP2023538284A (ja) 2020-08-04 2023-09-07 ダイセルナ ファーマシューティカルズ， インコーポレイテッド Ｐｌｐ１発現を阻害するための組成物及び方法
TW202221120A (zh) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
JP7476422B2 (ja) 2020-08-05 2024-04-30 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｌｐａ発現を阻害するための組成物及び方法
CN116761886A (zh) 2020-10-08 2023-09-15 迪克纳制药公司 选择性递送寡核苷酸至胶质细胞
WO2022218941A2 (en) 2021-04-12 2022-10-20 Boehringer Ingelheim International Gmbh Compositions and methods for inhibiting ketohexokinase (khk)
KR20230171431A (ko) 2021-04-14 2023-12-20 다이서나 파마수이티컬, 인크. Pnpla3 발현을 조절하기 위한 조성물 및 방법
CA3213775A1 (en) 2021-04-19 2022-10-27 Utsav SAXENA Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
AR125992A1 (es) 2021-05-28 2023-08-30 Novo Nordisk As Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
CN117897483A (zh) 2021-08-25 2024-04-16 戴瑟纳制药公司 用于抑制α-1抗胰蛋白酶表达的组合物和方法
US12234456B2 (en) 2021-12-01 2025-02-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating APOC3 expression
KR20250005108A (ko) 2022-04-15 2025-01-09 다이서나 파마수이티컬, 인크. Scap 활성을 조절하기 위한 조성물 및 방법
JP2025516677A (ja) 2022-05-12 2025-05-30 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｍａｐｔの発現を阻害するための組成物及び方法
KR20250024534A (ko) 2022-05-13 2025-02-18 다이서나 파마수이티컬, 인크. Snca 발현을 억제하기 위한 조성물 및 방법
TWI868755B (zh) 2022-06-24 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
TW202511486A (zh) 2023-07-28 2025-03-16 美商黛瑟納製藥公司 用於程式化死亡配體受體（ｐｄ－ｌ１）表現之組成物和方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
WO1988000975A1 (en) 1986-08-01 1988-02-11 Genetics Institute, Inc. High level inducible expression of heterologous genes
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6821724B1 (en) 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
ES2300257T3 (es) 1999-02-26 2008-06-16 The University Of British Columbia Terapia antisentido contra trpm-2.
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
GB9907048D0 (en) 1999-03-27 1999-05-19 Karobio Ab Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU782142B2 (en) 1999-12-07 2005-07-07 Sumitomo Chemical Company, Limited Mutant ERalpha and test systems for transactivation
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
GB0008936D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Vectors
US6649341B1 (en) 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US7227007B2 (en) 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
WO2002096943A1 (en) 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
WO2003008578A2 (en) 2001-07-20 2003-01-30 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying gene targets for treating cancer
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
AU2003214882A1 (en) 2002-01-23 2003-09-02 Mayo Foundation For Medical Education And Research Polycystic kidney disease nucleic acids and proteins
EP1465910A4 (en) 2002-02-20 2005-03-16 Sirna Therapeutics Inc INHIBITION OF GENE EXPRESSION OF CHECKPOINT KINASE-1 (CHK-1) IMPROVED BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACIDS
JP2003265184A (ja) 2002-03-18 2003-09-24 Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho 被検者におけるグルココルチコイド製剤の有効性の検査方法
NZ546806A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
EP1534728A4 (en) 2002-05-20 2005-10-26 Pharmacia Corp ANTISENSE MODULATION OF GLUCOCORTICOID RECEPTOR EXPRESSION
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1546180B1 (en) 2002-08-16 2013-07-03 Rexahn Pharmaceuticals, Inc. Use of antisense oligonucleotides to inhibit the expression of akt-1
AU2003298556A1 (en) 2002-08-19 2004-05-04 Regulome Corporation Functional sites
CA2494764C (en) 2002-08-21 2013-04-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003295387A1 (en) 2002-11-05 2004-06-03 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US7785778B2 (en) 2002-11-25 2010-08-31 University Of Copenhagen Porcine polymorphisms and methods for detecting them
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
AU2004274021B2 (en) 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
NZ548254A (en) 2003-12-23 2008-09-26 Santaris Pharma As Oligomeric compounds for the modulation of BCL-2
US20050164271A1 (en) 2004-01-20 2005-07-28 Sanjay Bhanot Modulation of glucocorticoid receptor expression
EP2397563A3 (en) 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US20060263798A1 (en) 2005-02-11 2006-11-23 International Business Machines Corporation System and method for identification of MicroRNA precursor sequences and corresponding mature MicroRNA sequences from genomic sequences
JP2006320271A (ja) * 2005-05-20 2006-11-30 Tokyo Institute Of Technology 低分子化合物とタンパク質の結合評価方法
EP1941040A1 (en) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
CA3044969A1 (en) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’修飾二環式核酸類似体
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物

Similar Documents

Publication Publication Date Title
JP2015501155A5 (enExample)
JP2014530004A5 (enExample)
JP2014511686A5 (enExample)
IL264288A (en) Methods and compositions for modulating apolipoprotein(a) expression
JP2014513954A5 (enExample)
JP2014521310A5 (enExample)
JP2016501513A5 (enExample)
NL300963I9 (nl) Een verbinding omvattende een gemodificeerd oligonucleotide met een nucleobasensequentie bestaande uit 20 gekoppelde nucleosiden volgens EP-B1-2563920 conclusie 1 (SEQ ID NO: 80), waarbij de gemodificeerde oligonucleotide omvat: een tussenruimtesegment dat bestaat uit tien gekoppelde deoxynucleosiden; een 5' vleugelsegment dat bestaat uit vijf gekoppelde nucleosiden; en een 3' vleugelsegment dat bestaat uit vijf gekoppelde nucleosiden; waarbij het tussenruimtesegment is gepositioneerd tussen het 5' vleugelsegment en het 3' vleugelsegment, waarbij elke nucleoside van elk vleugelsegment een 2'-O-methoxyethylsuiker omvat; waarbij elke cytosine van het gemodificeerde oligonucleotide een 5-methylcytosine is, en waarbij elke internucleosidekoppeling van het gemodificeerde oligonucleotide een fosforothioaatkoppeling is; en in het bijzonder inotersen; en derivaten daarvan, zoals zouten ervan, waaronder natriumzouten, zoals beschermd door EP-B1-2563920.
JP2013516489A5 (enExample)
HRP20210244T1 (hr) Moduliranje eksprimiranja virusa hepatitisa b (hbv)
JP2015507625A5 (enExample)
JP2017510271A5 (enExample)
JP2011501962A5 (enExample)
RU2016116849A (ru) Композиции для модуляции экспрессии c90rf72
IL261901A (en) Compositions and methods for modulating apolipoprotein expression
FI2906696T4 (fi) Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
JP2017505116A5 (enExample)
JP2012050438A5 (enExample)
JP2016116520A5 (enExample)
JP2015536132A5 (enExample)
RU2016130110A (ru) Способы хирургической обработки путем резания и сшивания скобками
RU2011119479A (ru) Модуляция экспрессии фактора 11
RU2016129725A (ru) Модуляция экспрессии ангиопоэтин-подобного белка 3
RU2014115215A (ru) Антисмысловая регуляция экспрессии gcgr
JP2017505623A5 (enExample)